Before the First Symptom: Weighing the Decision to Test for Alzheimer's Genetic Risk

For most of human history, Alzheimer's disease arrived without warning. A misplaced set of keys, a forgotten name, a moment of confusion — and then, eventually, a diagnosis. Today, that timeline is shifting. Genetic screening and emerging blood-based biomarker tests are offering families something that was unimaginable a generation ago: a glimpse into the future, before a single symptom appears.

But a glimpse is not a certainty. And for many families already navigating Alzheimer's — or watching it unfold in a parent or grandparent — the question of whether to look is anything but simple.

What Genetic and Biomarker Testing Can Actually Tell You

The most widely discussed genetic marker in Alzheimer's research is the APOE4 allele, a variant of the apolipoprotein E gene. Inheriting one copy of APOE4 increases a person's lifetime risk of developing Alzheimer's by approximately three to four times compared to the general population. Inheriting two copies — one from each parent — can raise that risk by eight to twelve times, according to the National Institute on Aging.

It is critical to understand, however, that APOE4 is a risk factor, not a destiny. Many individuals who carry two copies of the gene never develop the disease. Many who develop Alzheimer's carry no copies at all. The gene influences probability; it does not write a guaranteed outcome.

More recently, blood-based biomarker tests have entered the conversation. These tests — some now commercially available and others still in research phases — can detect elevated levels of amyloid beta and tau proteins in the bloodstream, both of which are hallmarks of Alzheimer's pathology. In 2024, the FDA cleared the first blood test for amyloid plaque detection, a development that has meaningfully expanded the landscape of pre-symptomatic assessment.

Together, APOE4 genotyping and biomarker testing can paint a more complete picture of risk. Neither, however, provides a definitive answer about whether or when a person will develop dementia.

The Case for Knowing

For some individuals, particularly those with a strong family history of Alzheimer's, the argument for testing is rooted in practicality. Early awareness creates the opportunity for early action.

Those who test positive for elevated risk may choose to adopt lifestyle modifications — regular cardiovascular exercise, dietary changes, cognitive engagement, and aggressive management of blood pressure and sleep quality — all of which have demonstrated some evidence of protective benefit. They may also become eligible for clinical trials studying preventive interventions, contributing to research that could eventually benefit their own children.

From a legal and financial planning standpoint, knowing one's risk status while cognitively intact allows an individual to complete advance directives, establish powers of attorney, and make informed decisions about long-term care insurance before a diagnosis makes those conversations more fraught. Families who have watched a parent navigate Alzheimer's without adequate planning in place understand the value of that preparation.

There is also an emerging psychological argument: for certain personality types, uncertainty itself is the greater burden. Some people find that having concrete information — even difficult information — allows them to organize their lives with greater intention and less ambient anxiety.

The Case for Not Knowing

The counterargument is equally serious. Learning that you carry APOE4 or show elevated amyloid levels does not come with a treatment that will prevent the disease. Unlike BRCA gene testing for breast cancer, where a positive result can prompt concrete preventive surgeries, a positive Alzheimer's risk result currently offers no equivalent clinical intervention.

Research published in journals including JAMA Neurology has documented significant psychological consequences following genetic disclosure, including elevated rates of anxiety, depression, and what some researchers describe as "anticipatory grief" — mourning a loss that has not yet occurred and may never occur in the way feared.

There is also the matter of insurance. While the Genetic Information Nondiscrimination Act (GINA) prohibits health insurers and employers from discriminating based on genetic test results, it does not extend to life insurance, disability insurance, or long-term care insurance. Individuals who test positive may find themselves facing limited options in those markets.

The Family Dimension

Perhaps the most underappreciated complexity of genetic testing is that the results do not belong only to the person who tests. A positive APOE4 result in one sibling carries direct implications for all biological siblings and for adult children. This reality can create tension: one family member's desire to know may effectively pressure others into confronting information they would rather not have.

Genetic counselors — professionals specifically trained to help individuals and families navigate these decisions — strongly recommend consulting with one before pursuing any form of Alzheimer's genetic testing. A certified genetic counselor can help you clarify your personal motivations, prepare for a range of possible outcomes, and develop a thoughtful plan for how and whether to communicate results to family members.

If you do decide to share results, timing and framing matter enormously. Ideally, conversations with adult children or siblings should happen in person, with adequate time for questions and emotional processing. Presenting the information as a shared family resource — rather than a verdict — can help reframe what might otherwise feel like frightening news.

A Decision That Belongs to You

There is no universally correct answer to the question of whether to test. Medical professionals, ethicists, and families themselves remain genuinely divided. What the research does suggest is that the decision should be made deliberately, with access to good information and professional support — not impulsively, out of fear or curiosity alone.

If you are considering genetic or biomarker testing, speak first with your primary care physician or a neurologist who specializes in memory disorders. Ask for a referral to a genetic counselor. And give yourself permission to decide that not knowing is, for now, the right answer for you.

Families touched by Alzheimer's already carry a great deal. The choice of whether to carry this particular knowledge — and when, and with whom to share it — is one of the most personal decisions you may face. There is wisdom in approaching it with both scientific clarity and deep self-awareness.